Omma, 393 patient HCQ late treatment study: 28% lower mortality [p=0.3], 50% lower ICU admission [p=0.004], and 17% shorter hospitalization [p=0.007] https://c19p.org/omma
copied to clipboard
Hydroxychloroquine shortened hospital stay and reduced intensive care unit admissions in hospitalized COVID-19 patients
et al., The Journal of Infection in Developing Countries, doi:10.3855/jidc.14933
Retrospective 393 hospitalized COVID-19 patients in Turkey, showing lower ICU admission and shorter hospitalization time with HCQ. There was no significant difference for mortality. Severity was higher in the HCQ group with greater baseline ventilation, high flow oxygen, fever, and dyspnea.
|
risk of death, 28.2% lower, RR 0.72, p = 0.30, treatment 17 of 213 (8.0%), control 20 of 180 (11.1%), NNT 32.
|
|
risk of ICU admission, 50.2% lower, RR 0.50, p = 0.004, treatment 23 of 213 (10.8%), control 39 of 180 (21.7%), NNT 9.2.
|
|
hospitalization time, 16.7% lower, relative time 0.83, p = 0.007, treatment 213, control 180.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Omma et al., 1/31/2022, retrospective, Turkey, Europe, peer-reviewed, 11 authors, study period 1 April, 2020 - 31 December, 2020.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.